期刊文献+

血管紧张素受体拮抗剂治疗心力衰竭的价值仍未确定 被引量:4

下载PDF
导出
摘要 肾素-血管紧张素-醛固酮系统(RAAS)在心力衰竭发生和发展中起重要作用的观点已经得到广泛认可,其证据主要来自两个方面:一方面,基础研究显示,血管紧张素(Aug)Ⅱ是一种强力血管收缩物质,是心肌细胞和成纤维细胞的生长因子,并通过释放醛固酮引起水钠潴留,通过促进去甲肾上腺素和内皮素等物质而参与过度激活体内其它神经激素系统。RAAS激活的即刻作用是增加心脏的前、后负荷,长期效应则包括导致不利的心脏重构过程。后者以心室扩大、室壁肥厚和心腔变形为特征,所有这些改变均促使左室功能异常进行性加重;另一方面。
作者 施仲伟
出处 《中国医药导刊》 2000年第3期31-32,共2页 Chinese Journal of Medicinal Guide
  • 相关文献

参考文献1

二级参考文献1

  • 1Pitt B,Segal R,Martinez FA,etal.Randomized trial of losartan versus captopril in patients over 65 with heart failure(Evaluation of Losartan in The Elderly Study,ELITE).Lancet,1997, 349(9054): 747~752

共引文献2

同被引文献43

  • 1刘国仗.胰岛素抵抗及其检测方法[J].中华心血管病杂志,1996,24(1):3-4. 被引量:125
  • 2Ambrosioni E, Borghi C, Magnani B, for the Survival of Myocardial Infarction Long - term Evaluation (SMILE) study investigators.The effect of the angiotensin - converting - enzyme inhibitor zofenopril on mortality and morbidity after anterior myocardial infarction. N Engl J Med, 1995;332(2): 80- 85.
  • 3Pfeffer MA, Braunwald E, Moye LA, et al. Effect of captopril on mortality and morbidity in patients with left ventricular dysfunction after myocardial infarction: results of the survival and ventricular enlargement trial. N Engl J Med, 1992;327(10) : 669 - 677.
  • 4Kober L, Torp- Pedersen C, Carlsen JE, et al. A clinical trial of the angiotensin - converting - enzyme inhibitor trandolapril in patients with left ventricular dysfunction after myocardial infarction.New Engl J Med, 1995;333(25) : 1670- 1676.
  • 5The Acute Infarction Ramipril Efficacy (AIRE) Study Investigators.Effect of ramipril on mortality and morbidity of survivors of acute myocardial infarction with clinical evidence of heart failure.Lancet, 1993; 342(8875) : 821 - 828.
  • 6Ryan TJ, Antman EM, Brooks NH, et al. 1999 update: ACC/AHA guidelines for the management of patients with acute myocardial infarction: executive summary and recommendations: a report of the American College of Cardiology / American Heart Association Task Force on Practice Guidelines (Committee on Management of Acute Myocardial Infarction). Circulation, 1999; 100(9) : 1016 - 1030.
  • 7Dickstein K, Kjekshus J, and the OPTIMAAL Steering Committee,for the OPTIMAAL Study Group. Effects of losartan and captopril on mortality and mordility in higih - risk patients after acute myocardial infaretion: the OPTIMAAL randomized trial. Lancet,2002;360(9335) : 752- 760.
  • 8Dahlof B, Devereux RB, Kjeldsen S, et al. Cardiovascular morbidity and mortality in the Losartan Intervention For Endpoint reduction in hypertension study (LIFE) : a randomized trial against atenolol. Lancet, 2002;359(9311): 995-1003.
  • 9Pitt B, Segal R, Martinez FA, et al. Randomized trial of losartan versus captopril in patients over 65 with heart failure (Evaluation of Losartan in The Elderly Study, ELITE) Lancet, 1997; 349(9054) : 747 - 752.
  • 10Pitt B, Poole - Wilson PA, Segal R, et al. Effects of losartan versus captopril on mortality in patients with symptomatic heart failure: rationale, design, and baseline characteristics of patients in the Losartan Heart Failure Survival Study- - ELITE Ⅱ. J Cardiac Fail, 1999, 5(2): 146- 154.

二级引证文献8

相关作者

内容加载中请稍等...

相关机构

内容加载中请稍等...

相关主题

内容加载中请稍等...

浏览历史

内容加载中请稍等...
;
使用帮助 返回顶部